Validation of Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Analysis of Data from Patients Seeking Compensation from the New South Wales Dust Diseases Board-Reference-Cited by-同舟云学术

Validation of Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Analysis of Data from Patients Seeking Compensation from the New South Wales Dust Diseases Board

Published:2013-01 Issue:1 Volume:14 Page:70-77
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Kao Steven C.,Vardy Janette,Chatfield Mark,Corte Peter,Pavlakis Nick,Clarke Christopher,van Zandwijk Nico,Clarke Stephen

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference34 articles.

1. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma;Vogelzang;J Clin Oncol,2003

2. Cancer in NSW: Incidence and Mortality Report 2008;Tracey,2010

3. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience;Curran;J Clin Oncol,1998

4. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the cancer and Leukemia Group B;Herndon;Chest,1998

5. Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ki67 Tumor Expression Predicts Treatment Benefit Achieved by Macroscopic Radical Lung-Preserving Surgery in Pleural Mesothelioma—A Retrospective Multicenter Analysis;Cancers;2024-05-10

2. Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund;Tumori Journal;2024-02-19

3. Diagnostic, prognostic, and therapeutic implications of genetic profiling in pleural mesothelioma;Journal of Cancer Metastasis and Treatment;2023

4. The clinical utility of the LENT score in patients with malignant pleural mesothelioma;Tuberk Toraks;2022-12-12

5. Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma;Journal of Thoracic Oncology;2021-11